MX2010004251A - Anticuerpo anti-bst2. - Google Patents

Anticuerpo anti-bst2.

Info

Publication number
MX2010004251A
MX2010004251A MX2010004251A MX2010004251A MX2010004251A MX 2010004251 A MX2010004251 A MX 2010004251A MX 2010004251 A MX2010004251 A MX 2010004251A MX 2010004251 A MX2010004251 A MX 2010004251A MX 2010004251 A MX2010004251 A MX 2010004251A
Authority
MX
Mexico
Prior art keywords
antibody
bst2d
bst2
tissue
expresses
Prior art date
Application number
MX2010004251A
Other languages
English (en)
Inventor
Yumiko Kamagawa
Koji Ishida
Minkwon Cho
Sahori Namiki
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of MX2010004251A publication Critical patent/MX2010004251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Como una medida se clasifican anticuerpos BST2 empleando su capacidad para enlazar a variantes de división de un antígeno BST2 humano. Como resultado, se puede obtener con éxito un anticuerpo BST2 con la capacidad de reconocer en forma específica BST2D (la cual es una substancia reportada como expresada en una célula de cáncer en un alto nivel). El anticuerpo puede enlazar en forma específica a una célula que expresa BST2D. Cuando el anticuerpo se utiliza para terapia, se hace posible inhibir el enlace no específico del anticuerpo a un tejido diferente a un tejido objetivo (en donde el enlace no específico puede originar la disminución en la concentración del anticuerpo en la sangre). También se describe un agente de diagnóstico que comprende el anticuerpo, el cual puede detectar en forma específica un tejido que expresa BST2D.
MX2010004251A 2007-10-16 2008-10-16 Anticuerpo anti-bst2. MX2010004251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007269470 2007-10-16
PCT/JP2008/068794 WO2009051201A1 (ja) 2007-10-16 2008-10-16 抗bst2抗体

Publications (1)

Publication Number Publication Date
MX2010004251A true MX2010004251A (es) 2010-08-30

Family

ID=40567462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004251A MX2010004251A (es) 2007-10-16 2008-10-16 Anticuerpo anti-bst2.

Country Status (14)

Country Link
US (2) US8529896B2 (es)
EP (1) EP2210939A4 (es)
JP (1) JP5558825B2 (es)
KR (1) KR20100090258A (es)
CN (2) CN104031150A (es)
AU (1) AU2008312858A1 (es)
BR (1) BRPI0817427A8 (es)
CA (1) CA2702939A1 (es)
IL (1) IL205073A (es)
MX (1) MX2010004251A (es)
NZ (1) NZ585394A (es)
RU (1) RU2010119450A (es)
UA (1) UA105760C2 (es)
WO (1) WO2009051201A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2012162698A1 (en) 2011-05-26 2012-11-29 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of immune disorders
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
WO2014066271A1 (en) * 2012-10-22 2014-05-01 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
KR102524920B1 (ko) 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
US10435470B2 (en) * 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
US20230235074A1 (en) * 2020-06-19 2023-07-27 Board Of Regents, The University Of Texas System Anti-bst2 antibodies targeting bst2 long isoform
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US305121A (en) * 1884-09-16 Razor-strop
ZA948016B (en) * 1993-10-15 1995-05-31 Toshio Hirano A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof
BR9811094A (pt) 1997-02-12 2000-07-18 Chugai Pharmaceutical Co Ltd Agente terapêutico para tumores linfáticos
AU2640299A (en) 1998-02-25 1999-09-15 Chugai Seiyaku Kabushiki Kaisha Genomic gene encoding hm1.24 antigen protein and promoter thereof
JP4450555B2 (ja) * 2000-12-28 2010-04-14 協和発酵キリン株式会社 新規モノクローナル抗体
JP3986439B2 (ja) * 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
WO2002084290A1 (fr) 2001-04-13 2002-10-24 Chugai Seiyaku Kabushiki Kaisha Procede permettant de quantifier l'expression d'antigenes
EP1693069B1 (en) 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor
CA2570602A1 (en) 2004-06-11 2006-01-26 Ginkgo Biomedical Research Institute Co., Ltd. Agents for regulating the activity of interferon-producing cells
WO2006013923A1 (ja) 2004-08-05 2006-02-09 Ginkgo Biomedical Research Institute Co., Ltd. 自己免疫疾患を伴う関節炎の治療剤
JPWO2006054748A1 (ja) 2004-11-22 2008-06-05 Ｓｂｉバイオテック株式会社 腎炎の治療剤
US20080299128A1 (en) 2006-06-20 2008-12-04 Myung Kim Effect of Bst2 on inflammation

Also Published As

Publication number Publication date
CN101952426A (zh) 2011-01-19
NZ585394A (en) 2012-05-25
KR20100090258A (ko) 2010-08-13
CN101952426B (zh) 2014-04-16
IL205073A (en) 2014-07-31
WO2009051201A1 (ja) 2009-04-23
CN104031150A (zh) 2014-09-10
IL205073A0 (en) 2010-11-30
RU2010119450A (ru) 2011-11-27
CA2702939A1 (en) 2009-04-23
EP2210939A1 (en) 2010-07-28
BRPI0817427A2 (pt) 2015-06-16
UA105760C2 (uk) 2014-06-25
BRPI0817427A8 (pt) 2019-01-29
HK1153502A1 (en) 2012-03-30
US20130336967A1 (en) 2013-12-19
US8529896B2 (en) 2013-09-10
JP5558825B2 (ja) 2014-07-23
US20100278832A1 (en) 2010-11-04
AU2008312858A1 (en) 2009-04-23
JPWO2009051201A1 (ja) 2011-03-03
EP2210939A4 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
MX2010004251A (es) Anticuerpo anti-bst2.
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
BR112012009854A8 (pt) proteínas de ligação de antígeno il-23 humana
CY1121294T1 (el) Αντι-ilt7 αντισωμα
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
CO6680693A2 (es) Anticuerpos humanos recombinantes, tanto humanizados como quiméricos, los cuales en lazan especificamente a ox40 humano
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
MX2010000537A (es) Anticuerpos monoclonales contra glipicano-3.
EA201590671A1 (ru) Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
BR112012012887A2 (pt) minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
BR122018069446B8 (pt) método in vitro para detectar a presença de um célula de câncer em um indivíduo
BR112012022802A2 (pt) uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
EP1860119A4 (en) ANTI-IGSF4 ANTIBODY AND ITS USE
BR112018005322A2 (pt) anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
CO6630164A2 (es) Proteinas que se unen al tnf-a
AR073775A1 (es) Anticuerpos biespecificos anti-vegf/anti- ang -2
ES2570632T3 (es) Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA201071068A1 (ru) Антитела к tyrp1
AR063840A1 (es) Anticuerpos humanos monoclonales para btla y metodos de uso

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration